Bologna

• PROSPECTIVE EVALUATION OF THE DDR GENES ALTERATION TO PREDICT RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED UROTHELIAL CANCER Recruiting
  2024-516450-21-00 6 2024-12-31 metastatic or locally advanced urothelial cancer
• A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 65 years with alcohol-re … Recruiting
  2024-511596-15-00 4 2024-12-26 Liver Diseases, Alcoholic
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Recruiting
  2024-511188-26-00 5 2024-12-20 Relapsed/refractory multiple myeloma in patients who have received 1 t
• A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting
  2023-508813-18-00 4 2024-12-18 Refractory Focal Onset Epilepsy
• A trial to learn if AZD5492 is safe and works alone and in combination with other cancer treatments in adults with B-cell blood cancers. Recruiting
  2024-511099-34-00 1 2024-12-12 B-Cell Malignancies
• MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting
  2024-516839-27-00 4 2024-12-09 BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
• A single-arm phase II study of cetuximab plus platinum and taxane-based chemotherapy followed by AVElumab and Cetuximab as first-line therap … Recruiting
  2024-512053-24-00 4 2024-12-05 recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSC
• This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting
  2023-504713-76-00 5 2024-12-03 Dermatitis atopic
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 Metastatic HER2-positive breast cancer
• Prospective phase IIb study to evaluate the efficacy of laparoscopic electrochemotherapy in the treatment of locally advanced pancreatic can … Recruiting
  2024-519067-17-00 4 2024-12-02 Locally Advanced Pancreatic Cancer
• A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2 trial to evaluate the efficacy and safety of BP1.7881 in … Recruiting
  2023-508949-40-00 4 2024-11-29 Eosinophilic esophagitis
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensate … Recruiting
  2024-512895-36-00 5 2024-11-25 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Bomedemstat vs Hydroxyurea for Essential Thrombocythemia Recruiting
  2023-505232-36-00 5 2024-11-15 Essential thrombocythemia
• Intravenous Fosfomycin in hospitalized patients with complicated urinary tract infections due to Third-generation cephalosporinresistant Ent … Recruiting
  2024-516591-15-00 6 2024-11-12 urinary tract infections
• A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia Recruiting
  2023-510288-37-00 3 2024-11-01 Relapsed and/or refractory Acute Myeloid Leukemia
• A Long-term Extension Study of Guselkumab in Pediatric Participants Recruiting
  2023-509560-16-00 5 2024-10-29 Juvenile psoriatic arthritis (jPsA)
• A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc … Recruiting
  2024-511319-91-00 5 2024-10-23 Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
• Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting
  2023-504724-25-00 5 2024-10-16 Primary Myelofibrosis
• An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch … Recruiting
  2024-516782-36-00 4 2024-10-15 metastatic or recurrent endometrial or ovarian carcinosarcoma
• An extension study to find out if multiple treatment cycles of rozanolixizumab are safe and work in children with myasthenia gravis Recruiting
  2022-502075-34-00 5 2024-10-08 Generalized Myasthenia Gravis
• A study to test the efficacy and safety of riliprubart against the usual treatment of intravenous immunoglobulin (IVIg) in people with chron … Recruiting
  2023-508338-33-00 5 2024-10-01 Chronic Inflammatory Demyelinating Polyneuropathy
• A Study to Evaluate ARV-393 in Adult Participants with Advanced Non-Hodgkin’s Lymphoma Recruiting
  2023-510136-36-00 1 2024-09-27 Advanced Non-Hodgkin’s Lymphoma

Showing 289–312 of 868 trials